Tirzepatide Medicinal

Tirzepatide Weight Loss: The Trial Evidence

Before the details

Tirzepatide weight loss — the reduction in body weight measured in the large clinical trials — is among the largest ever documented for an approved medicine. In SURMOUNT-1, the largest obesity trial to date, people lost an average of about 21% of their starting body weight over 18 months at the highest dose, compared with about 3% with a placebo. That means someone starting at 250 pounds might expect to lose roughly 50 pounds on average at the highest dose, though individual results vary widely. The drug does not work for everyone — about 10–15% of people in trials lost less than 5% of their weight — and weight tends to return when the medicine is stopped. This page summarises the trial evidence for tirzepatide weight loss across the SURMOUNT, SURPASS, and head-to-head programmes, with every number cited to the study that measured it.

SURMOUNT-1: the landmark 72-week obesity trial

SURMOUNT-1 (Jastreboff AM, et al., N Engl J Med 2022; n=2539; PMID 35658024) enrolled adults with a BMI of 30 or higher (or 27+ with at least one weight-related complication) and without type 2 diabetes. Participants received once-weekly subcutaneous tirzepatide — starting at 2.5 mg for four weeks and escalating stepwise over 20 weeks to maintenance doses of 5, 10, or 15 mg — or placebo for 72 weeks [4].

Mean weight change at week 72:

  • 5 mg: -15.0% versus -3.1% with placebo
  • 10 mg: -19.5% versus -3.1% with placebo
  • 15 mg: -20.9% versus -3.1% with placebo

Proportion achieving >=15% weight loss: 40% (5 mg), 57% (10 mg), 62% (15 mg) versus 7% (placebo).

The most common adverse events were gastrointestinal and mostly mild to moderate, occurring primarily during dose escalation [4].

Extended follow-up from SURMOUNT-1 (Jastreboff AM, et al., N Engl J Med 2025; PMID 39536238) confirmed sustained weight reduction at longer follow-up and documented reduced progression to type 2 diabetes in participants with baseline prediabetes [18].

SURMOUNT-5: head-to-head against a comparator GLP-1 agonist

SURMOUNT-5 (Aronne LJ, et al., N Engl J Med 2025; n=751; PMID 40353578) was a phase 3b open-label head-to-head trial in adults with obesity but without type 2 diabetes [5]. Participants were randomised to the maximum tolerated dose of tirzepatide (10 or 15 mg) or the maximum tolerated dose of a comparator GLP-1 receptor agonist (1.7 or 2.4 mg) once weekly for 72 weeks.

Least-squares mean weight change at week 72:

  • Tirzepatide: -20.2%
  • Comparator: -13.7%
  • P<0.001

Tirzepatide also produced a greater reduction in waist circumference and higher proportions of participants reaching >=10%, >=15%, >=20%, and >=25% weight loss. The most common adverse events in both groups were gastrointestinal [5].

A network meta-analysis of 31 randomised trials (n>35,000; Pan XH, et al., Obesity 2024; PMID 38413012) found tirzepatide 15 mg ranked in the top three across weight-related parameters and had the highest efficacy for achieving >=15% weight loss compared with all comparators including selective GLP-1 receptor agonists (risk ratio 10.24, 95% CI 6.42–16.34) [33].

SURMOUNT-2: obesity plus type 2 diabetes

SURMOUNT-2 (Garvey WT, et al., Lancet 2023; n=938; PMID 37385275) extended the obesity indication to adults with type 2 diabetes [6 — ref 6 in this page]. Tirzepatide 10 and 15 mg once weekly over 72 weeks produced substantial body-weight reductions versus placebo in this population as well, confirming that the weight-loss efficacy observed in SURMOUNT-1 extends to people with comorbid type 2 diabetes.

A further extension, SURMOUNT-3 (Wadden TA, et al., Nat Med 2023; PMID 37840095), randomised participants who had already achieved >=5% weight reduction during a 12-week intensive lifestyle intervention to tirzepatide or placebo for 72 weeks. Additional mean weight change from randomisation to week 72: -18.4% with tirzepatide versus +2.5% with placebo (treatment difference -20.8 percentage points; P<0.001) [34]. This confirmed a combinatorial benefit: tirzepatide added to prior lifestyle weight loss produced substantially more reduction than lifestyle alone.

Cardiometabolic dividends of tirzepatide weight loss

The cardiometabolic improvements tracked with the degree of weight lost. In a post hoc SURMOUNT-1 analysis (Linetzky B, et al., Ann Intern Med 2025; n=1605; PMID 40550133), the most striking improvements at >=35% weight loss included systolic blood pressure -14.2 mmHg, diastolic blood pressure -9.2 mmHg, waist circumference -32.4 cm, and HOMA-IR (a measure of insulin resistance) -59.7% [13]. Insulin resistance and HbA1c improvements were detectable even at <5% weight reduction, whereas lipid (triglyceride, HDL, LDL) improvements emerged primarily after >10% reduction [13].

A meta-analysis of seven randomised trials (Kanbay M, et al., Diabetes Obes Metab 2023; PMID 37700437) found dose-dependent reductions in systolic blood pressure (-4.20 to -5.77 mmHg across doses), total cholesterol (-3.76% to -5.93%), and LDL-cholesterol and triglycerides, with increases in HDL-cholesterol [35].

For more on the body-composition specifics — fat versus lean mass — see tirzepatide muscle loss and Tirzepatide research.

Weight regain after stopping

Weight regain after stopping tirzepatide is well documented. The SURMOUNT-4 trial (Aronne LJ, et al., JAMA 2024; PMID 38078870) found that participants switched to placebo after an initial period of tirzepatide treatment regained weight, while those continuing tirzepatide kept losing weight [27]. A pooled withdrawal analysis found a mean weight regain of approximately 9.7 kg in the treatment group versus continued weight loss in those maintained on therapy [28].

A SURMOUNT-4 post hoc analysis (Horn DB, et al., JAMA Intern Med 2026; PMID 41284285) documented that cardiometabolic risk factors — blood pressure, waist circumference, insulin resistance — worsened in parallel with weight regain [28]. This framing, consistent across the programme, positions tirzepatide as a chronic treatment for obesity rather than a short-course intervention — analogous to how blood-pressure or cholesterol medicines work.